Maxim Group analyst Jason McCarthy downgraded Proteon Therapeutics (NASDAQ: PRTO) from Buy ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Downgrades

Proteon Therapeutics (PRTO) PT Lowered to $1 at BairdMarch 28, 2019 11:19 AM Proteon Therapeutics (PRTO) Phase 3 PATENCY-2 Clinical Trial of Vonapanitase in Radiocephalic Arteriovenous Fistulas Didn't Meet Co-Primary EndpointsMarch 28, 2019 8:02 AM Proteon Therapeutics Announces Top-Line Results From Phase 3 PATENCY-2 Clinical Trial of Vonapanitase in Radiocephalic Arteriovenous FistulasMarch 28, 2019 8:00 AM